Intellia Therapeutics Ends Co-Development Agreement With Regeneron
By Chris Wack
Intellia Therapeutics said in a filing that it has notified Regeneron Pharmaceuticals that it is opting out of its Factor IX co-development and co-funding agreement, which Intellia and Regeneron entered into in May 2020.
The agreement will end 180 days after Intellia's written notice to Regeneron, and the company will continue to have obligations related to the co-development of gene-editing products directed to Factor IX until the effective date of termination.
Upon termination, Intellia will no longer be obligated for sharing 35% of the development costs, or be entitled to receive 35% of the profits, for gene-editing products.
Intellia will continue to support Regeneron with the development of gene-editing products under a previous license and collaboration agreement.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 22, 2024 10:23 ET (14:23 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks